keyword
MENU ▼
Read by QxMD icon Read
search

neutropenic fever

keyword
https://www.readbyqxmd.com/read/28077045/association-of-time-to-antibiotics-and-clinical-outcomes-in-adult-hematologic-malignancy-patients-with-febrile-neutropenia
#1
Allison R Butts, Christina Carracedo Bachmeier, Emily V Dressler, Meng Liu, Ann Cowden, Jeff Talbert, Val R Adams
Objective The objective of this study was to determine the clinical impact of time to antibiotic administration in adult inpatients who have hematologic malignancies and develop febrile neutropenia. Methods A retrospective chart review was conducted to screen for all febrile neutropenia events amongst adult hematologic malignancy patients between 1 January 2010 and 1 September 2014. All included patients were admitted to the hospital at the time of fever onset, having been admitted for a diagnosis other than febrile neutropenia...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28075196/typhlitis-neutropenic-enterocolitis-in-patients-with-acute-leukemia-a-review
#2
Rodrigo Portugal, Marcio Nucci
Typhlitis is an abdominal complication of cancer chemotherapy, affecting mostly patients receiving intensive chemotherapeutic regimens with high potential to induce mucosal damage, such as patients with acute leukemia. Despite being relatively frequent, there are no randomized trials or high-quality cohort studies addressing important aspects of the diagnosis and management of the disease. Areas covered: In this review we discuss the gaps in the literature, acknowledging that the evidences for recommendations regarding the management of typhlitis are mostly expert opinion...
January 11, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28038931/safety-of-same-day-pegfilgrastim-administration-in-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel-with-or-without-carboplatin
#3
Mehmet Asim Bilen, Diana H Cauley, Bradley J Atkinson, Hsiang-Chun Chen, Diana H Kaya, Xuemei Wang, Raghu Vikram, Shi-Ming Tu, Paul G Corn, Jeri Kim
INTRODUCTION: Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment with or without carboplatin in patients with mCRPC. We also evaluated the frequency of urinary tract inflammation during treatment. PATIENTS AND METHODS: Between September 2010 and September 2014, 151 consecutive patients with mCRPC underwent cabazitaxel treatment with or without the addition of carboplatin at a single institution...
December 13, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28013359/comparison-of-engraftment-following-different-stem-cell-mobilization-modalities-in-patients-with-multiple-myeloma-treated-with-a-uniform-induction-regimen-containing-bortezomib-cyclophosphamide-and-dexamethasone
#4
Noam Benyamini, Irit Avivi, Eldad J Dann, Tsila Zuckerman, Noa Lavi, Tami Katz
Bortezomib-based induction followed by autologous stem cell transplantation is a common treatment for multiple myeloma (MM). Stem cell (SC) mobilization with granulocyte-colony stimulating factor (G-CSF) alone has become an alternative to G-CSF combined with chemotherapeutic agents. This study aimed to compare the efficacy of the two mobilization modalities following induction with a uniform regimen containing bortezomib, cyclophosphamide and dexamethasone (VCD). We retrospectively evaluated results of SC mobilization using either G-CSF alone or combined with high-dose cyclophosphamide (HD-CY) in MM patients after VCD induction...
December 24, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28003106/st-segment-elevations-in-a-patient-with-neutropenic-fever
#5
Avash Das, Arjun Gupta, Saumya Das
No abstract text is available yet for this article.
December 18, 2016: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/27910184/clinical-significance-of-pre-transplant-circulating-cd3-cd4-cd161-cell-frequency-on-the-occurrence-of-neutropenic-infections-after-allogeneic-stem-cell-transplantation
#6
Tae Woo Kim, Sung-Eun Lee, Ji-Young Lim, Da-Bin Ryu, Young-Woo Jeon, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min, Chang-Ki Min
BACKGROUND: Few studies have been performed to identify factors that are associated with an increased risk of infections during the neutropenic period in patients undergoing allogeneic stem cell transplantation (allo-SCT). The aim of this study was to identify the host immune cells responsible for infections before engraftment. METHODS: A total of 282 patients who underwent allo-SCT were enrolled. Peripheral blood samples were collected before conditioning therapy...
December 2, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27904453/outcome-of-severe-infections-in-afebrile-neutropenic-cancer-patients
#7
Ksenija Strojnik, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, Bostjan Seruga
BACKGROUND: In some neutropenic cancer patients fever may be absent despite microbiologically and/or clinically confirmed infection. We hypothesized that afebrile neutropenic cancer patients with severe infections have worse outcome as compared to cancer patients with febrile neutropenia. PATIENTS AND METHODS: We retrospectively analyzed all adult cancer patients with chemotherapy-induced neutropenia and severe infection, who were admitted to the Intensive Care Unit at our cancer center between 2000 and 2011...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27888542/clinical-outcomes-of-extended-versus-intermittent-infusion-of-piperacillin-tazobactam-in-critically-ill-patients-a-prospective-clinical-trial
#8
Sheung-Yin Fan, Hoi-Ping Shum, Wing-Yee Cheng, Yat-Hei Chan, Sik-Yin McShirley Leung, Wing-Wa Yan
STUDY OBJECTIVE: To determine whether critically ill patients receiving extended-infusion (EI) piperacillin/tazobactam would have improved clinical outcomes compared with patients receiving intermittent infusions. DESIGN: Single-center, open-label, prospective study. SETTING: Twenty-two-bed intensive care unit (ICU) in a regional hospital in Hong Kong. PATIENTS: A total of 367 adults who had a diagnosis of either bacterial infection or neutropenic fever and had received treatment with piperacillin/tazobactam for at least 48 hours between December 1, 2013, and August 31, 2015...
January 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/27857902/severe-congenital-cyclic-neutropenia-a-case-report
#9
Vidyavathi H Patil, Shivayogi M Hugar, Girish Balikai, Sudha Patil
Congenital cyclic neutropenia syndrome is a constitutional genetic disorder which is characterized by very low number of neutrophils (neutropenia). Patients suffering from this disorder clinically present with neutropenia at early age, history of recurrent fever, ulcerations in the oral cavity, gingivitis, and other recurrent infections. This paper describes a case report of a child with recurrent mouth ulcers, fever, and later diagnosed with severe congenital cyclic neutropenia. This also emphasizes the importance of identification of rare causes of immunosuppressive conditions in children presenting with recurrent oral ulcers and poor dental hygiene, to prevent long-term complications of oral cavity and also morbidity and mortality secondary to neutropenic sepsis...
October 2016: International Journal of Applied and Basic Medical Research
https://www.readbyqxmd.com/read/27803612/painless-neutropenic-enterocolitis-in-a-patient-undergoing-chemotherapy
#10
E J Chow, K D Bishop
CASE DESCRIPTION: A 60-year-old man developed painless neutropenic enterocolitis after induction chemotherapy for newly diagnosed acute myelogenous leukemia. The patient had recurrent fever while neutropenic, without experiencing abdominal pain or tenderness on physical examination. His diagnosis was delayed by the fact that he had no localizing symptoms. DISCUSSION: Neutropenic enterocolitis is a common complication, generally occurring in patients who are severely neutropenic; the condition presents with fever and abdominal pain...
October 2016: Current Oncology
https://www.readbyqxmd.com/read/27790720/a-phase-2-trial-of-high-dose-lenalidomide-in-patients-with-relapsed-refractory-higher-risk-myelodysplastic-syndromes-and-acute-myeloid-leukaemia-with-trilineage-dysplasia
#11
Amer M Zeidan, B Douglas Smith, Hetty E Carraway, Ivana Gojo, Amy DeZern, Steven D Gore
Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but there is limited data in the RR setting. This phase II trial included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint was response rate using the 2006 International Working Group criteria...
October 28, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27782906/trabectedin-in-advanced-desmoplastic-round-cell-tumors-a-retrospective-single-center-series
#12
Benjamin Verret, Charles Honore, Sarah Dumont, Philippe Terrier, Julien Adam, Andrea Cavalcanti, Isabelle Sourrouille, Guillaume Klausner, Marion Ahlenc-Gelas, Nicolas Kiavue, Gabriella Domitrescu, Lamiae El Amarti, Olivier Mir, Axel Le Cesne
Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy that occurs with unpredictable chemosensitivity and limited treatment options in the advanced setting. Prognosis is poor, and exploring new treatment options for such diseases is difficult because of its rarity. Clinical activity of trabectedin for advanced DSRCT was scarcely reported in the literature. Here, we report a series of six patients treated with trabectedin for an unresectable DSRCT. After receiving trabectedin, two patients had stable disease with a time to progression of 3 and 3...
January 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27738797/impact-of-antibacterial-prophylaxis-during-reinduction-chemotherapy-for-relapse-refractory-acute-myeloid-leukemia
#13
Beejal R Ganti, Bernard L Marini, Jerod Nagel, Dale Bixby, Anthony J Perissinotti
PURPOSE: This study evaluated the impact of antibacterial prophylaxis with levofloxacin in relapsed/refractory acute myeloid leukemia (AML) patients. METHODS: This was a retrospective, single-center, cohort study. Adult patients with relapsed/refractory AML admitted for reinduction chemotherapy between November 1, 2006 and June 15, 2015 were screened for inclusion. A protocol initiating levofloxacin prophylaxis was implemented on December 1, 2013. Patients receiving hypomethylating agents (decitabine/azacitidine) were not administered antibacterial prophylaxis and thus not included in this analysis...
February 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27725464/ectopic-adrenocorticotropic-hormone-syndrome-caused-by-neuroendocrine-carcinoma-of-the-colon
#14
Kazuyo Fujimoto, Takatoshi Nakashima, Kazunari Sasaki, Kenichi Hayashi, Masao Hanafusa, Shiei Yoshida, Satoshi Myojo, Shun-Ichi Yoshida, Shigeaki Sawai, Nobuya Sano
A 48-year-old woman with a history of autoimmune hemolytic anemia and taking long-term corticosteroid therapy presented with a 3-month history of general fatigue, abdominal distension, and pigmentation. A computed tomography scan of the abdomen showed a tumor in the sigmoid colon and multiple metastatic nodules in the liver. A colonoscopy revealed an obstructing mass with the presence of an irregular ulcer in the sigmoid colon. Following biopsy and histopathological analysis, the patient was diagnosed with neuroendocrine carcinoma (NEC) of the colon...
2016: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/27648294/phase-ii-study-of-neo-adjuvant-chemotherapy-for-locally-advanced-gastric-cancer
#15
Alex Yuang-Chi Chang, Kian Fong Foo, Wen-Hsin Koo, Simon Ong, Jimmy So, Daniel Tan, Khong Hee Lim
BACKGROUND: Neoadjuvant chemotherapy improves survival of locally advanced gastric cancer patients. However, benefit is limited and the best regimen remains controversial. OBJECTIVES: Our primary objective of this prospective, multicenter phase 2 study was to evaluate the pathological complete response rate (PCR) with 2 cycles of docetaxel and capecitabine. METHODS: To be eligible, patients had to have histologically documented gastric cancer, a ECOG performance status 0 or 1, T3or4 Nany M0 staging after oesophagogastroduodenoscopy (OGD), endoscopic ultrasound (EUS), CT scan of thorax and abdomen, and negative laparoscopic examination and peritoneal washing...
2016: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/27640002/comparison-of-two-dose-levels-of-cyclophosphamide-for-successful-stem-cell-mobilization-in-myeloma-patients
#16
Nils Winkelmann, Max Desole, Inken Hilgendorf, Thomas Ernst, Herbert G Sayer, Christa Kunert, Lars-Olof Mügge, Andreas Hochhaus, Sebastian Scholl
INTRODUCTION: Even in the era of proteasome inhibitors and immunomodulatory drugs, the autologous stem cell transplantation after high-dose melphalan continues to represent a standard approach for myeloma patients in first-line therapy. Different mobilization chemotherapies before stem cell apheresis have been published while cyclophosphamide at a dose level of up to 4 g/m(2) has been evaluated and is commonly applied. In contrast, lower dose levels of cyclophosphamide (e.g., 1.5 g/m(2)) did not result in a sufficient collection of stem cells...
December 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27590107/a-phase-i-ii-study-of-escalating-doses-of-bortezomib-in-conjunction-with-high-dose-melphalan-as-a-conditioning-regimen-for-salvage-autologous-peripheral-blood-stem-cell-transplantation-in-patients-with-multiple-myeloma
#17
Noa Biran, Scott D Rowley, David H Vesole, Shijia Zhang, Michele L Donato, Joshua Richter, Alan P Skarbnik, Andrew Pecora, David S Siegel
Escalating doses of bortezomib with high-dose melphalan was evaluated as as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with relapsed or refractory multiple myeloma (MM). MM patients with less than a partial remission (PR) (or 50% reduction) compared to their pretransplantation paraprotein parameters after a prior ASCT with melphalan conditioning, or who were in relapse after a prior autologous transplantation, were eligible for study. Bortezomib was dose escalated in steps of 1, 1...
August 31, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27575541/phase-ii-study-of-propylene-glycol-free-melphalan-combined-with-carmustine-etoposide-and-cytarabine-for-myeloablative-conditioning-in-lymphoma-patients-undergoing-autologous-stem-cell-transplantation
#18
Amanda F Cashen, Theresa Fletcher, Connie Ceriotti, Feng Gao, Armin Ghobadi, Ravi Vij, Keith Stockerl-Goldstein, John DiPersio, Camille Abboud
The lyophilized formulation of melphalan has several limitations based on its marginal solubility, limited stability after reconstitution, and the requirement to reconstitute it in propylene glycol (PG). PG-free melphalan (Evomela; Spectrum Pharmaceuticals, Irvine CA) overcomes these limitations by using the solubilizing agent Captisol (Ligand Pharmaceuticals, Inc., LaJolla CA) to improve the stability of the reconstituted melphalan and avoid the potential toxicities of PG. This phase II study investigated the safety and efficacy of high-dose PG-free melphalan when included in the carmustine, etoposide, and cytarabine (BEAM) regimen for adult patients with non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)...
August 26, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27502729/dose-dense-fec-followed-by-docetaxel-versus-docetaxel-plus-cyclophosphamide-as-adjuvant-chemotherapy-in-women-with-her2-negative-axillary-lymph-node-positive-early-breast-cancer-a-multicenter-randomized-study-by-the-hellenic-oncology-research-group-horg
#19
D Mavroudis, A Matikas, N Malamos, P Papakotoulas, S Kakolyris, I Boukovinas, A Athanasiadis, N Kentepozidis, N Ziras, P Katsaounis, E Saloustros, V Georgoulias
BACKGROUND: Sequential administration of anthracycline and taxane is the current standard of care adjuvant regimen for node-positive early breast cancer. Due to long-term toxicity concerns, anthracycline-free regimens have been developed. We compared a sequential dose-dense anthracycline and taxane regimen with the anthracycline-free regimen of docetaxel and cyclophosphamide. PATIENTS AND METHODS: In this randomized, non-inferiority, phase III trial, women with HER2-negative invasive breast cancer and at least one positive axillary lymph node were randomized to receive either epirubicin (75 mg/m(2)), 5-fluorouracil (500 mg/m(2)) and cyclophosphamide (500 mg/m(2)) every 2 weeks for four cycles, followed by four cycles of docetaxel (75 mg/m(2)) every 2 weeks with prophylactic G-CSF support (FEC → D) or docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 21 days for six cycles (TC)...
October 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27491498/weekly-vinorelbine-and-paclitaxel-in-older-patients-with-advanced-non-small-cell-lung-cancer-a-phase-ii-fred-and-pamela-buffet-cancer-center-clinical-trials-network-study
#20
Mary M Huerter, Jane L Meza, M Sitki Copur, Addison Tolentino, Alissa S Marr, Marsha Ketcham, Holly DeSpiegelaere, Susan Kruse, Mary E Kos, Karin Swenson, Sarah E Radniecki, Anne Kessinger, Apar Kishor Ganti
OBJECTIVE: Platinum-based doublet chemotherapy is the standard for most patients with advanced non-small cell lung cancer (NSCLC). Toxicity concerns limit chemotherapy for patients over 70years. Vinorelbine and paclitaxel are effective as single agents in advanced NSCLC. This phase II study evaluates safety and efficacy of a combination of these two agents in patients >70years with advanced NSCLC. MATERIALS AND METHODS: Patients with treatment naïve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8...
August 1, 2016: Journal of Geriatric Oncology
keyword
keyword
45469
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"